Eli Lilly (LLY)
773.71
+3.83 (0.50%)
NYSE · Last Trade: Jun 9th, 5:25 PM EDT
Detailed Quote
Previous Close | 769.88 |
---|---|
Open | 771.95 |
Bid | 771.00 |
Ask | 773.75 |
Day's Range | 767.59 - 779.29 |
52 Week Range | 677.09 - 972.53 |
Volume | 2,255,007 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | 6.000 (0.78%) |
1 Month Average Volume | 4,226,805 |
Chart
About Eli Lilly (LLY)
Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
News & Press Releases
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via Investor's Business Daily · June 9, 2025
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via Benzinga · June 9, 2025

Via The Motley Fool · June 4, 2025
Via The Motley Fool · June 7, 2025
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via MarketBeat · June 7, 2025
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025

China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.
Via Stocktwits · June 4, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Via Benzinga · June 4, 2025

Dive deep into two popular dividend ETFs to determine which is right for your portfolio.
Via The Motley Fool · June 4, 2025

The company hopes the deal will help it snag business in the UK, building a similar model to its U.S. platform.
Via Investor's Business Daily · June 3, 2025

Seasonal trends highlight 10 S&P 500 stocks with strong June performance. Tesla leads the list, joined by consistent gainers like Eli Lilly.
Via Benzinga · June 2, 2025

A significant trading signal occurred for Eli Lilly stock, as it demonstrated a power inflow at $734.98, after which LLY rose up to 1.5%.
Via Benzinga · June 2, 2025

Via PR Leap · June 2, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Friday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · May 30, 2025